genentech inc american biotechnology corporation headquartered south san francisco california became independent subsidiary roche genentech research early development operates independent center within historically company regarded worlds first biotechnology july genentech employed company founded venture capitalist robert swanson biochemist herbert boyer considered pioneer field recombinant dna technology boyer colleague stanley norman cohen demonstrated restriction enzymes could used scissors cut dna fragments interest one source ligated similarly cut plasmid cohen returned laboratory academia swanson contacted boyer found boyer worked arthur riggs keiichi itakura beckman research institute group became first successfully express human gene bacteria produced hormone somatostatin david goeddel dennis kleid added group contributed success synthetic human insulin f hoffmannla roche ag acquired majority stake genentech acquired tanox first acquisition deal tanox started developing xolair development completed collaboration novartis genentech acquisition allowed genentech keep march roche acquired genentech buying shares didnt already control approximately july genentechroche acquired seragon pipeline smallmolecule cancer drug candidates million cash upfront additional billion payments dependent successful development products seragons genentech pioneering researchdriven biotechnology continued conduct rd internally well genentechs research collaborations include genentechs corporate headquarters south san francisco california genentech additional manufacturing facilities vacaville california oceanside california hillsboro oregon december genentech sold porri√±o spain facility lonza acquired exclusive right purchase lonzas mammalian cell culture manufacturing facility construction singapore june genentech began construction development e coli manufacturing facility also singapore worldwide production lucentis ranibizumab injection bulk drug substancecitation needed company announced plans close manufacturing facility south san francisco expanding manufacturing capabilities genentech donor center health care strategies nongovernmental organization lobbies united states government issues related genentech inc political action committee us federal political action committee pac created aggregate contributions members employees families donate candidates federal november genentech agreed pay university california san francisco million settle nineyearold patent dispute ucsf sued genentech million compensation alleged theft technology developed university covered patentcitation needed genentech claimed developed protropin recombinant somatotropinhuman growth hormone independently ucsf jury ruled universitys patent valid july wasnt able decide whether protropin based upon ucsf research protropin drug used treat dwarfism genentechs first marketed drug billion sales contributed greatly position industry leadercitation needed settlement divided follows million university california general fund million three inventors two collaborating scientists million towards new teaching research campus ucsf million support universitywide new york times reported genentechs talking points health care reform appeared verbatim official statements several members congress national health care reform two us representatives joe wilson blaine luetkemeyer issued written statements one reasons long supported us biotechnology industry homegrown success story engine job creation country unfortunately many largest companies would seek enter biosimilar market made money outsourcing research foreign countries like india statement originally drafted lobbyists genentech genentech also cohosts health equity symposium collaboration healthcare institutions community organizations address inequities among diverse genentech following awards diversity inclusion efforts httpsenwikipediaorgwikigenentech